Emiliano Tamburini

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Metastatic Colorectal Cancer

Ejection Fraction

Top Venues

OncoTargets and therapy

Cancer management and research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Valentina Fanotto, Daniele Rossini, Mariaelena Casagrande, Francesca Bergamo, Andrea Spagnoletti, Daniele Santini, Carlotta Antoniotti, Samanta Cupini, Francesca Daniel, Vincenzo Nasca, Guglielmo Vetere, Alberto Zaniboni, Beatrice Borelli, Martina Carullo, Veronica Conca, Alessandro Passardi, Emiliano Tamburini, Gianluca Masi, Nicoletta Pella, Chiara Cremolini
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. Cancers 15 (22) (2023)
Carlotta Antoniotti, Alessandra Boccaccino, Robert S Seitz, Mirella Giordano, Aurelie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J Nielsen, Jerome Galon, Matthew Gordon Varga, Brock L Schweitzer, Chiara Cremolini
An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Matteo Donadon, Angela Palmisano, Mariano Bizzarri, Roberto Ceriani, Luigi Veneroni, Gabriele Donati, Davide Tassinari, Massimo Giuseppe Viola, Emiliano Tamburini, Guido Torzilli
Impact of Oocyte Extract Supplement on Quality of Life after Hepatectomy for Liver Tumours: A Prospective, Multicentre, Double-Blind Randomized Clinical Trial. Cancers 15 (10) (2023)
Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo, Federica Marmorino, Francesca Bergamo, Emiliano Tamburini, Alessandro Passardi, Giovanni Randon, Sabina Murgioni, Beatrice Borelli, Angela Buonadonna, Mirella Giordano, Gabriella Fontanini, Veronica Conca, Vincenzo Formica, Massimo Aglietta, Roberto Bordonaro, Giuseppe Aprile, Gianluca Masi, Luca Boni, Chiara Cremolini
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Valentina Burgio, Massimo Iavarone, Giovanni Giuseppe Di Costanzo, Fabio Marra, Sara Lonardi, Emiliano Tamburini, Piscaglia Fabio, Gianluca Masi, Ciro Celsa, Francesco Giuseppe Foschi, Marianna Silletta, Daniela Caterina Amoruso, Margherita Rimini, Mariangela Bruccoleri, Raffaella Tortora, Claudia Campani, Caterina Soldà, Massimo Giuseppe Viola, Antonella Forgione, Fabio Conti, Francesca Salani, Silvia Catanese, Carmelo Marco Giacchetto, Claudia Fulgenzi, Carmine Coppola, Pietro Lampertico, Antonio Pellino, Gabriele Rancatore, Giuseppe Cabibbo, Francesca Ratti, Federica Pedica, Angelo Della Corte, Massimo Colombo, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Stefano Cascinu
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer management and research 13 (2021)
Stefano Cascinu, Marco Puzzoni, Francesco Montagnani, Giorgia Marisi, Emiliano Tamburini, Alessandro Cucchetti, Leonardo Solaini, Francesco Giuseppe Foschi, Fabio Conti, Giorgio Ercolani, Stefano Cascinu, Mario Scartozzi
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. OncoTargets and therapy 12 (2019)